Concurrent β-blocker Use is Associated With Improved Outcome in Esophageal Cancer Patients Who Undergo Chemoradiation: A Retrospective Matched-pair Analysis.
Journal
American journal of clinical oncology
ISSN: 1537-453X
Titre abrégé: Am J Clin Oncol
Pays: United States
ID NLM: 8207754
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
pubmed:
13
10
2020
medline:
20
2
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
β-blocker use has been associated with improved outcomes in a number of different malignancies; however, the impact of β-blockade in esophageal cancer is not been well characterized. We compared the outcomes of esophageal cancer patients based on β-blocker usage. The charts of all 418 patients treated with radiation for esophageal cancer at our institution from April 2010 to October 2018 were analyzed. Patients who underwent treatment with palliative intent or did not finish treatment were excluded. β-blocker use was determined from the medication list at time of pretreatment consultation. There were 291 esophageal cancer patients who received neoadjuvant/definitive chemoradiation therapy. The median follow-up for the cohort was 22.5 months (interquartile range: 9.6 to 41.0 mo). Within the cohort, 27.8% (n=81) of patients were taking β-blockers at the time of treatment. Those taking β-blockers had significantly improved distant control (22.2% vs. 37.9%; P=0.035). Concomitant β-blocker use was significantly associated with improved progression-free survival (P<0.001, hazard ratio=0.42 [0.27-0.66]) and overall survival (P=0.002, hazard ratio=0.55 [0.38-0.81]) on Cox regression analysis. Propensity score-matched pairs were created using tumor stage, nodal stage, sex, neoadjuvant versus definitive therapy, Karnofsky Performance Status, and aspirin use. This matched-pair analysis showed a significant progression-free survival (P=0.005) benefit in esophageal cancer patients taking β-blockers. Concurrent β-blocker use is common within patients receiving concurrent chemoradiation for esophageal cancer. Esophageal cancer patients who received chemoradiation while taking β-blockers demonstrated significant benefits in survival-based outcomes.
Sections du résumé
BACKGROUND
β-blocker use has been associated with improved outcomes in a number of different malignancies; however, the impact of β-blockade in esophageal cancer is not been well characterized. We compared the outcomes of esophageal cancer patients based on β-blocker usage.
METHODS
The charts of all 418 patients treated with radiation for esophageal cancer at our institution from April 2010 to October 2018 were analyzed. Patients who underwent treatment with palliative intent or did not finish treatment were excluded. β-blocker use was determined from the medication list at time of pretreatment consultation.
RESULTS
There were 291 esophageal cancer patients who received neoadjuvant/definitive chemoradiation therapy. The median follow-up for the cohort was 22.5 months (interquartile range: 9.6 to 41.0 mo). Within the cohort, 27.8% (n=81) of patients were taking β-blockers at the time of treatment. Those taking β-blockers had significantly improved distant control (22.2% vs. 37.9%; P=0.035). Concomitant β-blocker use was significantly associated with improved progression-free survival (P<0.001, hazard ratio=0.42 [0.27-0.66]) and overall survival (P=0.002, hazard ratio=0.55 [0.38-0.81]) on Cox regression analysis. Propensity score-matched pairs were created using tumor stage, nodal stage, sex, neoadjuvant versus definitive therapy, Karnofsky Performance Status, and aspirin use. This matched-pair analysis showed a significant progression-free survival (P=0.005) benefit in esophageal cancer patients taking β-blockers.
CONCLUSIONS
Concurrent β-blocker use is common within patients receiving concurrent chemoradiation for esophageal cancer. Esophageal cancer patients who received chemoradiation while taking β-blockers demonstrated significant benefits in survival-based outcomes.
Identifiants
pubmed: 33044232
pii: 00000421-202012000-00010
doi: 10.1097/COC.0000000000000768
pmc: PMC7855691
mid: NIHMS1629444
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
889-894Subventions
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13
pubmed: 13130116
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Arch Intern Med. 2011 Apr 25;171(8):779-81
pubmed: 21518948
JAMA Netw Open. 2020 Jun 1;3(6):e207199
pubmed: 32602907
J Clin Oncol. 2011 Jul 1;29(19):2635-44
pubmed: 21632503
Clin Oncol (R Coll Radiol). 2016 May;28(5):317-26
pubmed: 26712086
Radiat Res. 2019 Jun;191(6):585-589
pubmed: 31021732
Nat Commun. 2020 Apr 14;11(1):1821
pubmed: 32286326
Oncotarget. 2011 Oct;2(10):797-809
pubmed: 22006582
J Cancer Res Clin Oncol. 2014 Jul;140(7):1179-88
pubmed: 24671228
Eur J Cancer Prev. 2017 Jul;26(4):357-364
pubmed: 27275735
Cancer Epidemiol. 2011 Aug;35(4):309-19
pubmed: 21470937
Mol Cancer. 2011 Nov 26;10:146
pubmed: 22118662
Cancer Res. 2017 Oct 15;77(20):5639-5651
pubmed: 28819022
Cancer. 2020 Sep 1;126(17):3991-4001
pubmed: 32533792
Clin Lung Cancer. 2015 Mar;16(2):128-36
pubmed: 25450873
Medicine (Baltimore). 2015 Jul;94(27):e1097
pubmed: 26166098
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9
pubmed: 21933972
Ann Oncol. 2013 Mar;24(3):609-17
pubmed: 22898040
Nat Commun. 2015 Mar 10;6:6426
pubmed: 25756236
J Clin Oncol. 2005 Apr 1;23(10):2310-7
pubmed: 15800321
Ann Oncol. 2013 May;24(5):1312-9
pubmed: 23300016
Medicine (Baltimore). 2015 Jun;94(24):e719
pubmed: 26091452
Br J Anaesth. 2018 Jul;121(1):45-57
pubmed: 29935594
N Engl J Med. 2012 Oct 25;367(17):1596-606
pubmed: 23094721
Br J Clin Pharmacol. 2011 Jul;72(1):157-61
pubmed: 21453301
Radiat Oncol. 2010 Oct 26;5:98
pubmed: 20977754
Pancreas. 2009 Jan;38(1):94-100
pubmed: 19106745